M-4112
- Generic Name
- M-4112
First-in-Human Study of MS201408-0005A as Single Agent and in Combinations
Phase 1
Terminated
- Conditions
- Metastatic or Locally Advanced Unresectable Solid Tumors
- Interventions
- First Posted Date
- 2017-10-11
- Last Posted Date
- 2020-02-06
- Target Recruit Count
- 15
- Registration Number
- NCT03306420
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸University of TX M.D. Anderson Cancer Center-Investigational Cancer Therapeutics Partner, Houston, Texas, United States
🇺🇸South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath